Demographic and clinical characteristics for patients at the time of intent to CAR-T
| Characteristic . | Single-case agreement . | Total (n = 65) . | P value . | |
|---|---|---|---|---|
| No (n = 21) . | Yes (n = 44) . | |||
| Age, mean (SD) | 69.9 (8.71) | 55.2 (8.85) | 59.9 (11.14) | <.0001∗ |
| Sex, n (%) | .2575† | |||
| F | 6 (28.6) | 19 (43.2) | 25 (38.5) | |
| M | 15 (71.4) | 25 (56.8) | 40 (61.5) | |
| Race, n (%) | ||||
| Black or African American | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Chose not to disclose | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Other, Hispanic, or Latino | 0 (0.0) | 2 (4.5) | 2 (3.1) | |
| White | 21 (100.0) | 39 (88.6) | 60 (92.3) | |
| White, Hispanic | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Race, n (%) | .2958‡ | |||
| Not White/UNK | 0 (0.0) | 4 (9.1) | 4 (6.2) | |
| White | 21 (100.0) | 40 (90.9) | 61 (93.8) | |
| ECOG at iCAR-T, n (%) | .4526† | |||
| 0 | 3 (16.7) | 10 (26.3) | 13 (23.2) | |
| 1 | 13 (72.2) | 26 (68.4) | 39 (69.6) | |
| 2 | 2 (11.1) | 1 (2.6) | 3 (5.4) | |
| 3 | 0 (0.0) | 1 (2.6) | 1 (1.8) | |
| Missing | 3 | 6 | 9 | |
| LDH at iCAR-T, n (%) | .5347† | |||
| High | 15 (71.4) | 28 (63.6) | 43 (66.2) | |
| Normal | 6 (28.6) | 16 (36.4) | 22 (33.8) | |
| Tumor burden, n (%) | .8575† | |||
| Not bulky | 11 (52.4) | 22 (50.0) | 33 (50.8) | |
| Bulky | 10 (47.6) | 22 (50.0) | 32 (49.2) | |
| Disease status at iCAR-T, n (%) | .0495† | |||
| Refractory | 6 (28.6) | 24 (54.5) | 30 (46.2) | |
| Relapsed | 15 (71.4) | 20 (45.5) | 35 (53.8) | |
| Pre-aph bridging, n (%) | .1572† | |||
| No | 17 (81.0) | 28 (63.6) | 45 (69.2) | |
| Yes | 4 (19.0) | 16 (36.4) | 20 (30.8) | |
| Post-aph bridging, n (%) | .3771† | |||
| No | 15 (71.4) | 24 (60.0) | 39 (63.9) | |
| Yes | 6 (28.6) | 16 (40.0) | 22 (36.1) | |
| Missing | 0 | 4 | 4 | |
| Days aph to infusion | .7756§ | |||
| Median (IQR) | 27.0 (26.0-28.0) | 27.0 (25.0-28.5) | 27.0 (26.0-28.0) | |
| Range | 25.0-106.0 | 0.0-71.0 | 0.0-106.0 | |
| Missing | 0 | 4 | 4 | |
| Days from iCAR-T to aph | <.0001§ | |||
| Median (IQR) | 17.0 (14.0-22.0) | 32.5 (25.5-43.5) | 28.0 (21.0-40.0) | |
| Range | 7.0-78.0 | 8.0-67.0 | 7.0-78.0 | |
| Missing | 0 | 4 | 4 | |
| Response at day 100, n (%) | .4168† | |||
| CR | 12 (57.1) | 18 (46.2) | 30 (50.0) | |
| Not CR | 9 (42.9) | 21 (53.8) | 30 (50.0) | |
| Missing | 0 | 5 | 5 | |
| CTIQ | .1658‡ | |||
| No | 0 (0%) | 5 (11.4%) | 5 (7.7%) | |
| Yes | 21 (100%) | 39 (88.6%) | 60 (92.3%) | |
| Characteristic . | Single-case agreement . | Total (n = 65) . | P value . | |
|---|---|---|---|---|
| No (n = 21) . | Yes (n = 44) . | |||
| Age, mean (SD) | 69.9 (8.71) | 55.2 (8.85) | 59.9 (11.14) | <.0001∗ |
| Sex, n (%) | .2575† | |||
| F | 6 (28.6) | 19 (43.2) | 25 (38.5) | |
| M | 15 (71.4) | 25 (56.8) | 40 (61.5) | |
| Race, n (%) | ||||
| Black or African American | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Chose not to disclose | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Other, Hispanic, or Latino | 0 (0.0) | 2 (4.5) | 2 (3.1) | |
| White | 21 (100.0) | 39 (88.6) | 60 (92.3) | |
| White, Hispanic | 0 (0.0) | 1 (2.3) | 1 (1.5) | |
| Race, n (%) | .2958‡ | |||
| Not White/UNK | 0 (0.0) | 4 (9.1) | 4 (6.2) | |
| White | 21 (100.0) | 40 (90.9) | 61 (93.8) | |
| ECOG at iCAR-T, n (%) | .4526† | |||
| 0 | 3 (16.7) | 10 (26.3) | 13 (23.2) | |
| 1 | 13 (72.2) | 26 (68.4) | 39 (69.6) | |
| 2 | 2 (11.1) | 1 (2.6) | 3 (5.4) | |
| 3 | 0 (0.0) | 1 (2.6) | 1 (1.8) | |
| Missing | 3 | 6 | 9 | |
| LDH at iCAR-T, n (%) | .5347† | |||
| High | 15 (71.4) | 28 (63.6) | 43 (66.2) | |
| Normal | 6 (28.6) | 16 (36.4) | 22 (33.8) | |
| Tumor burden, n (%) | .8575† | |||
| Not bulky | 11 (52.4) | 22 (50.0) | 33 (50.8) | |
| Bulky | 10 (47.6) | 22 (50.0) | 32 (49.2) | |
| Disease status at iCAR-T, n (%) | .0495† | |||
| Refractory | 6 (28.6) | 24 (54.5) | 30 (46.2) | |
| Relapsed | 15 (71.4) | 20 (45.5) | 35 (53.8) | |
| Pre-aph bridging, n (%) | .1572† | |||
| No | 17 (81.0) | 28 (63.6) | 45 (69.2) | |
| Yes | 4 (19.0) | 16 (36.4) | 20 (30.8) | |
| Post-aph bridging, n (%) | .3771† | |||
| No | 15 (71.4) | 24 (60.0) | 39 (63.9) | |
| Yes | 6 (28.6) | 16 (40.0) | 22 (36.1) | |
| Missing | 0 | 4 | 4 | |
| Days aph to infusion | .7756§ | |||
| Median (IQR) | 27.0 (26.0-28.0) | 27.0 (25.0-28.5) | 27.0 (26.0-28.0) | |
| Range | 25.0-106.0 | 0.0-71.0 | 0.0-106.0 | |
| Missing | 0 | 4 | 4 | |
| Days from iCAR-T to aph | <.0001§ | |||
| Median (IQR) | 17.0 (14.0-22.0) | 32.5 (25.5-43.5) | 28.0 (21.0-40.0) | |
| Range | 7.0-78.0 | 8.0-67.0 | 7.0-78.0 | |
| Missing | 0 | 4 | 4 | |
| Response at day 100, n (%) | .4168† | |||
| CR | 12 (57.1) | 18 (46.2) | 30 (50.0) | |
| Not CR | 9 (42.9) | 21 (53.8) | 30 (50.0) | |
| Missing | 0 | 5 | 5 | |
| CTIQ | .1658‡ | |||
| No | 0 (0%) | 5 (11.4%) | 5 (7.7%) | |
| Yes | 21 (100%) | 39 (88.6%) | 60 (92.3%) | |
aph, apheresis; ECOG, Eastern Cooperative Oncology Group performance status; F, female; IQR, interquartile range; LDH, lactate dehydrogenase; M, male; SD, standard deviation; UNK, unknown.
Equal variance 2 sample t test.
A χ2 test was used to determined the P value.
Fisher exact P value.
Wilcoxon rank sum P value.